ATE159426T1
(de)
*
|
1991-04-16 |
1997-11-15 |
Nippon Shinyaku Co Ltd |
Verfahren zur herstellung einer festen dispersion
|
SG43179A1
(en)
|
1991-12-18 |
1997-10-17 |
Warner Lambert Co |
A process for the prepatation of a solid dispersion
|
WO1995013794A1
(fr)
*
|
1993-11-18 |
1995-05-26 |
Nippon Shinyaku Co., Ltd. |
Procede pour produire une composition de medicament stable, et preparation pharmaceutique
|
SE9502244D0
(sv)
*
|
1995-06-20 |
1995-06-20 |
Bioglan Ab |
A composition and a process for the preparation thereof
|
AUPN814496A0
(en)
*
|
1996-02-19 |
1996-03-14 |
Monash University |
Dermal penetration enhancer
|
AU3508097A
(en)
|
1996-06-26 |
1998-01-14 |
Board Of Regents, The University Of Texas System |
Hot-melt extrudable pharmaceutical formulation
|
ATE273002T1
(de)
*
|
1996-06-28 |
2004-08-15 |
Schering Corp |
Feste lösung eines fungizids mit erhöhter bioverfügbarkeit
|
US20050004049A1
(en)
*
|
1997-03-11 |
2005-01-06 |
Elan Pharma International Limited |
Novel griseofulvin compositions
|
US5955475A
(en)
*
|
1997-06-30 |
1999-09-21 |
Endo Pharmaceuticals Inc. |
Process for manufacturing paroxetine solid dispersions
|
HN1998000115A
(es)
*
|
1997-08-21 |
1999-06-02 |
Warner Lambert Co |
Formas de dosificación farmacéuticas sólidas
|
CA2214895C
(en)
*
|
1997-09-19 |
1999-04-20 |
Bernard Charles Sherman |
Improved pharmaceutical composition comprising fenofibrate
|
US6376542B1
(en)
*
|
1997-12-19 |
2002-04-23 |
Bissell Homecare, Inc. |
Aqueous miticide compositions containing benzyl benzoate
|
US6107341A
(en)
*
|
1997-12-19 |
2000-08-22 |
Bissell Homecare, Inc. |
Aqueous miticide containing benzyl benzoate
|
JP2001526227A
(ja)
*
|
1997-12-22 |
2001-12-18 |
シェーリング コーポレイション |
バイオアベイラビリティーを高めた分子分散組成物
|
US6706283B1
(en)
|
1999-02-10 |
2004-03-16 |
Pfizer Inc |
Controlled release by extrusion of solid amorphous dispersions of drugs
|
DE19913606A1
(de)
*
|
1999-03-25 |
2000-09-28 |
Basf Ag |
Pulverförmige Solubilisationshilfsstoffe für feste pharmazeutische Darreichungsformen
|
DE19916383A1
(de)
*
|
1999-03-31 |
2000-10-05 |
Schering Ag |
Pharmazeutische Zusammensetzung mit einem Extrusionsstoff
|
WO2000072829A1
(en)
*
|
1999-05-28 |
2000-12-07 |
Abbott Laboratories |
Novel formulations comprising lipid-regulating agents
|
DE19929361A1
(de)
*
|
1999-06-25 |
2001-01-04 |
Basf Ag |
Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
|
DE60028754T2
(de)
*
|
1999-11-12 |
2007-05-31 |
Abbott Laboratories, Abbott Park |
Feste dispersion mit ritonavir, fenofibrat oder griseofulvin
|
DE10000792A1
(de)
|
2000-01-11 |
2001-07-19 |
Bernhard C Lippold |
Formulierungen von Wirkstoffen in Form einer festen Dispersion
|
DE10026698A1
(de)
|
2000-05-30 |
2001-12-06 |
Basf Ag |
Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
|
KR20040011549A
(ko)
|
2001-06-22 |
2004-02-05 |
화이자 프로덕츠 인크. |
저용해도 및(또는) 산-민감성 약물 및 중화된 산성중합체를 포함하는 제약 조성물
|
ATE444060T1
(de)
|
2001-06-22 |
2009-10-15 |
Pfizer Prod Inc |
Pharmazeutische zusammensetzungen enthaltend dispersionen aus arzneistoffen und neutralen polymeren
|
EP1469832B2
(en)
*
|
2002-02-01 |
2016-10-26 |
Bend Research, Inc. |
Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
|
MY140561A
(en)
*
|
2002-02-20 |
2009-12-31 |
Nycomed Gmbh |
Dosage form containing pde 4 inhibitor as active ingredient
|
GB0205253D0
(en)
*
|
2002-03-06 |
2002-04-17 |
Univ Gent |
Immediate release pharmaceutical granule compositions and a continuous process for making them
|
WO2003077923A1
(en)
*
|
2002-03-14 |
2003-09-25 |
Watson Pharmaceuticals, Inc. |
Progesterone oral drug delivery system
|
US7776314B2
(en)
|
2002-06-17 |
2010-08-17 |
Grunenthal Gmbh |
Abuse-proofed dosage system
|
CA2489865C
(en)
*
|
2002-06-25 |
2012-05-08 |
Acrux Dds Pty Ltd |
Transdermal delivery rate control using amorphous pharmaceutical compositions
|
US20050181032A1
(en)
*
|
2002-06-25 |
2005-08-18 |
Acrux Dds Pty Ltd. |
Metastable pharmaceutical compositions
|
JP2006518380A
(ja)
|
2003-01-31 |
2006-08-10 |
スミスクライン・ビーチャム・コーポレイション |
固体分散体組成物
|
WO2004069138A2
(en)
*
|
2003-02-03 |
2004-08-19 |
Novartis Ag |
Pharmaceutical formulation
|
ES2335498T3
(es)
|
2003-03-10 |
2010-03-29 |
Nycomed Gmbh |
Nuevo proceso para la preparacion de reflumilast.
|
MXPA05011626A
(es)
*
|
2003-04-29 |
2006-01-23 |
Akzo Nobel Nv |
Procedimiento de soldificacion con antisolvente.
|
PE20050150A1
(es)
*
|
2003-05-08 |
2005-03-22 |
Altana Pharma Ag |
Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
|
CL2004000983A1
(es)
*
|
2003-05-08 |
2005-03-04 |
Altana Pharma Ag |
Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
|
US8273371B2
(en)
|
2003-06-27 |
2012-09-25 |
Johan Adriaan Martens |
Crystalline mesoporous oxide based materials useful for the fixation and controlled release of drugs
|
GB0315012D0
(en)
*
|
2003-06-27 |
2003-07-30 |
Leuven K U Res & Dev |
Zeotiles
|
BRPI0413277A
(pt)
|
2003-08-04 |
2006-10-10 |
Pfizer Prod Inc |
composições farmacêuticas de adsorvatos de medicamentos amorfos e materiais que formam microfases lipofìlicas
|
DE10336400A1
(de)
|
2003-08-06 |
2005-03-24 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte Darreichungsform
|
DE102005005446A1
(de)
|
2005-02-04 |
2006-08-10 |
Grünenthal GmbH |
Bruchfeste Darreichungsformen mit retardierter Freisetzung
|
US20070048228A1
(en)
|
2003-08-06 |
2007-03-01 |
Elisabeth Arkenau-Maric |
Abuse-proofed dosage form
|
DE102004032051A1
(de)
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
|
DE10361596A1
(de)
|
2003-12-24 |
2005-09-29 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
|
US8377952B2
(en)
|
2003-08-28 |
2013-02-19 |
Abbott Laboratories |
Solid pharmaceutical dosage formulation
|
US8025899B2
(en)
|
2003-08-28 |
2011-09-27 |
Abbott Laboratories |
Solid pharmaceutical dosage form
|
KR20060085686A
(ko)
|
2003-10-10 |
2006-07-27 |
라이프사이클 파마 에이/에스 |
피브레이트를 포함하는 고형 제제
|
SI1691787T1
(sl)
*
|
2003-12-04 |
2008-10-31 |
Pfizer Prod Inc |
Postopek za pripravo farmacevtskih produktov iz več delcev
|
KR100629771B1
(ko)
*
|
2004-01-27 |
2006-09-28 |
씨제이 주식회사 |
결정성이 감소되거나 무정형화된 올티프라즈의 제조방법
|
US20050202079A1
(en)
*
|
2004-03-15 |
2005-09-15 |
Mylan Pharmaceuticals Inc. |
Novel orally administrable formulation of nitrofurantoin and a method for preparing said formulation
|
DE102004032049A1
(de)
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte, orale Darreichungsform
|
GB2418854B
(en)
*
|
2004-08-31 |
2009-12-23 |
Euro Celtique Sa |
Multiparticulates
|
DE102005005449A1
(de)
|
2005-02-04 |
2006-08-10 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
|
AU2006224619B2
(en)
*
|
2005-03-16 |
2012-06-07 |
Takeda Gmbh |
Taste masked dosage form containing roflumilast
|
EP1871346A4
(en)
*
|
2005-04-20 |
2012-07-18 |
Ctc Bio Inc |
PHARMACEUTICAL COMPOSITION WITH FREE BASE FROM SIBUTRAMIN AND MANUFACTURING METHOD THEREFOR
|
KR100627687B1
(ko)
*
|
2005-04-20 |
2006-09-25 |
주식회사 씨티씨바이오 |
시부트라민 유리염기 함유 조성물 및 이의 제조방법
|
DE102005023803A1
(de)
*
|
2005-05-19 |
2006-11-23 |
Basf Ag |
Verfahren zur Herstellung von festen Blends aus Polyvinylpyrrolidonen und ethoxilierten Fettsäurederivaten
|
KR20070025070A
(ko)
*
|
2005-08-31 |
2007-03-08 |
주식회사 대웅제약 |
시부트라민 및 계면활성제를 함유하는 고체분산체 및 그의제조방법
|
GB0612695D0
(en)
*
|
2006-06-27 |
2006-08-09 |
Univ Gent |
Process for preparing a solid dosage form
|
SA07280459B1
(ar)
|
2006-08-25 |
2011-07-20 |
بيورديو فارما إل. بي. |
أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
|
US20080132560A1
(en)
*
|
2006-11-21 |
2008-06-05 |
San-Laung Chow |
Solid dispersion composition
|
US20100016449A1
(en)
*
|
2006-12-21 |
2010-01-21 |
Boehringer Ingelheim International Gmbh |
Formulations with Improved Bioavailability
|
EP2249808A2
(en)
*
|
2008-01-11 |
2010-11-17 |
Cipla Limited |
Solid pharmaceutical dosage form
|
US8383152B2
(en)
|
2008-01-25 |
2013-02-26 |
Gruenenthal Gmbh |
Pharmaceutical dosage form
|
SI2273983T1
(sl)
|
2008-05-09 |
2016-11-30 |
Gruenenthal Gmbh |
Postopek za pripravo intermediatne praškaste formulacije in končne trdne odmerne oblike z uporabo stopnje strjevanja z razprševanjem
|
AU2010275755B2
(en)
|
2009-07-22 |
2014-04-24 |
Grünenthal GmbH |
Oxidation-stabilized tamper-resistant dosage form
|
TW201105316A
(en)
|
2009-07-22 |
2011-02-16 |
Gruenenthal Gmbh |
Hot-melt extruded pharmaceutical dosage form
|
MX346660B
(es)
*
|
2009-10-27 |
2017-03-28 |
Lupin Ltd |
Dispersion solida de rifaximina.
|
MX2013002377A
(es)
|
2010-09-02 |
2013-04-29 |
Gruenenthal Gmbh |
Forma de dosificacion resistente a manipulacion que comprende una sal inorganica.
|
CN103179954A
(zh)
|
2010-09-02 |
2013-06-26 |
格吕伦塔尔有限公司 |
包含阴离子聚合物的抗破碎剂型
|
ES2571735T3
(es)
|
2010-10-20 |
2016-05-26 |
Dsm Ip Assets Bv |
Composiciones biodegradables que soportan grupo hidrófilo colgante y dispositivos relacionados
|
CA3152557A1
(en)
*
|
2010-10-29 |
2012-05-03 |
Abbvie Inc. |
Solid dispersions containing an apoptosis-inducing agent
|
RS56527B1
(sr)
|
2011-07-29 |
2018-02-28 |
Gruenenthal Gmbh |
Tableta za trenutno oslobađanje leka rezistentna na zloupotrebu
|
US10201502B2
(en)
|
2011-07-29 |
2019-02-12 |
Gruenenthal Gmbh |
Tamper-resistant tablet providing immediate drug release
|
WO2013030789A1
(en)
|
2011-08-30 |
2013-03-07 |
Ranbaxy Laboratories Limited |
Pharmaceutical oral solid dosage form containing a poorly water soluble pde - iv inhibitor
|
MX356421B
(es)
|
2012-02-28 |
2018-05-29 |
Gruenenthal Gmbh |
Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico.
|
EA201401139A1
(ru)
|
2012-04-18 |
2015-03-31 |
Грюненталь Гмбх |
Устойчивая к разрушению и к сбросу дозы фармацевтическая лекарственная форма
|
US10064945B2
(en)
|
2012-05-11 |
2018-09-04 |
Gruenenthal Gmbh |
Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
|
KR102191562B1
(ko)
*
|
2012-11-07 |
2020-12-15 |
에스케이바이오팜 주식회사 |
난용성 약물의 고체분산체 및 이의 제조방법
|
BR112015026549A2
(pt)
|
2013-05-29 |
2017-07-25 |
Gruenenthal Gmbh |
forma de dosagem à prova de violação contendo uma ou mais partículas
|
CA2913209A1
(en)
|
2013-05-29 |
2014-12-04 |
Grunenthal Gmbh |
Tamper resistant dosage form with bimodal release profile
|
CA2917136C
(en)
|
2013-07-12 |
2022-05-31 |
Grunenthal Gmbh |
Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
|
WO2015071841A1
(en)
|
2013-11-12 |
2015-05-21 |
Druggability Technologies Holdings Limited |
Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
|
WO2015078891A1
(en)
|
2013-11-26 |
2015-06-04 |
Farmaceutici Formenti S.P.A. |
Preparation of a powdery pharmaceutical composition by means of cryo-milling
|
WO2015173195A1
(en)
|
2014-05-12 |
2015-11-19 |
Grünenthal GmbH |
Tamper resistant immediate release capsule formulation comprising tapentadol
|
MX2016015417A
(es)
|
2014-05-26 |
2017-02-22 |
Gruenenthal Gmbh |
Multiparticulas protegidas contra vertido de dosis etanolico.
|
US10085991B2
(en)
|
2014-12-04 |
2018-10-02 |
Merck Sharp & Dohme Corp. |
Formulation inhibiting effects of low acid environment
|
EP3285745A1
(en)
|
2015-04-24 |
2018-02-28 |
Grünenthal GmbH |
Tamper-resistant dosage form with immediate release and resistance against solvent extraction
|
JP2018526414A
(ja)
|
2015-09-10 |
2018-09-13 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護
|
CN113616599B
(zh)
*
|
2021-09-10 |
2022-11-18 |
宁夏医科大学 |
一种大黄素固体分散体及其制备方法与应用
|